Co-infection with HIV increases the morbidity and mortality associated with tuberculosis due to multiple factors including a poorly understood microbial synergy. We developed a novel small animal model of co-infection in the humanized mouse to investigate how HIV infection disrupts pulmonary containment of Mtb. Following dual infection, HIV-infected cells were localized to sites of Mtb-driven inflammation and mycobacterial replication in the lung. Consistent with disease in human subjects, we observed increased mycobacterial burden, loss of granuloma structure, and increased progression of TB disease, due to HIV co-infection. Importantly, we observed an HIV-dependent pro-inflammatory cytokine signature (IL-1β, IL-6, TNFα, and IL-8), neutrophil accumulation, and greater lung pathology in the Mtb-co-infected lung. These results suggest that in the early stages of acute co-infection in the humanized mouse, infection with HIV exacerbates the pro-inflammatory response to pulmonary Mtb, leading to poorly formed granulomas, more severe lung pathology, and increased mycobacterial burden and dissemination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808832 | PMC |
| http://dx.doi.org/10.1038/srep21522 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Theoretical modeling of hepatitis C acute infection in liver-humanized mice support pre-clinical assessment of candidate viruses for controlled-human-infection studies.
Sci Rep
December 2024
The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Stritch School of Medicine, Loyola University Chicago, 2160 S. First Ave., Maywood, IL, 60153, USA.
Designing and carrying out a controlled human infection (CHI) model for hepatitis C virus (HCV) is critical for vaccine development. However, key considerations for a CHI model protocol include understanding of the earliest viral-host kinetic events during the acute phase and susceptibility of the viral isolate under consideration for use in the CHI model to antiviral treatment before any infections in human volunteers can take place. Humanized mouse models lack adaptive immune responses but provide a unique opportunity to obtain quantitative understanding of early HCV kinetics and develop mathematical models to further understand viral and innate immune response dynamics during acute HCV infection.
View Article and Find Full Text PDFTreating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.
Lancet Respir Med
January 2025
Nuffield Department of Medicine, University of Oxford, Oxford, UK; King's Centre for Lung Health, School of Immunology and Microbial Sciences, King's College London, London, UK. Electronic address:
Background: Exacerbations of asthma and chronic obstructive pulmonary disease (COPD) are important events and are associated with critical illness. Eosinophilic inflammation is a treatable trait commonly found during acute exacerbations of asthma and COPD. We hypothesised that for patients with eosinophilic exacerbations, a single injection of benralizumab, a humanised monoclonal antibody against interleukin-5 receptor-α, alone or in combination with prednisolone, will improve clinical outcomes compared with prednisolone, the standard of care.
View Article and Find Full Text PDFAnti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection.
bioRxiv
November 2024
UCLA AIDS Institute, UCLA, Los Angeles, CA, USA, 90024.
Article Synopsis
- HSPC-based gene therapy shows potential for long-term HIV-1 remission after a single treatment, using a lentiviral vector to deliver three anti-HIV-1 genes.
- Two of the genes focus on preventing infection by targeting the CCR5 co-receptor and inhibiting fusion of the virus, while the third gene is designed to attack infected cells.
- The therapy was successful in humanized mouse models, significantly reducing HIV-1 viral load and allowing for safe removal of modified cells if necessary, demonstrating both effectiveness and safety of the approach.
Pro-inflammatory macrophages suppress HIV replication in humanized mice and co-cultures.
Front Immunol
November 2024
Department of Infectious Diseases and Hospital Epidemiology, University of Zurich, University Hospital of Zurich, Zurich, Switzerland.
Introduction: Very little is known about the role of macrophages as immune mediators during natural HIV infection. Humanized mice are an extremely valuable model for studying HIV pathogenesis. However, the presence of murine mononuclear phagocytes in these models represents a significant limitation for studying their human counterpart.
View Article and Find Full Text PDFSecondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies.
Mult Scler
December 2024
Department of Neurology-Neuroimmunology, Vall Hebron University Hospital and Multiple Sclerosis Centre of Catalonia (Cemcat) & Universitat Autònoma de Barcelona, Barcelona, Spain.
Article Synopsis
- - Organizing pneumonia (OP) has been identified in patients with inflammatory demyelinating diseases (IDDs) after COVID-19, particularly those treated with anti-CD20 therapies, but comprehensive data is scarce.
- - This study analyzed 19 patients with conditions like multiple sclerosis and neuromyelitis optica who developed COVID-19-associated OP; symptoms included intermittent fever, and most required hospitalization, but none died.
- - After about 1.5 years of follow-up, most lung issues resolved, although many patients experienced long-COVID symptoms; the study suggests that OP should be considered in anti-CD20-treated patients exhibiting specific CT findings and fever.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!